[
  {
    "ts": null,
    "headline": "AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026",
    "summary": "Buy AbbVie (ABBV) stock? See more on its 2025 EPS growth outlook from Skyrizi/Rinvoq, valuation at 14.4x FY27, key risks, and breakout targets.",
    "url": "https://finnhub.io/api/news?id=d80e17a1875bc5afec64470b2e58fd791a8ad091ce7f967f28b4a02b7cdb306d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767306250,
      "headline": "AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026",
      "id": 137962051,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Buy AbbVie (ABBV) stock? See more on its 2025 EPS growth outlook from Skyrizi/Rinvoq, valuation at 14.4x FY27, key risks, and breakout targets.",
      "url": "https://finnhub.io/api/news?id=d80e17a1875bc5afec64470b2e58fd791a8ad091ce7f967f28b4a02b7cdb306d"
    }
  }
]